Last reviewed · How we verify
faslodex dummy
Faslodex is a selective estrogen receptor degrader (SERD) that blocks estrogen receptors in breast cancer cells.
Faslodex is a selective estrogen receptor degrader (SERD) that blocks estrogen receptors in breast cancer cells. Used for Metastatic breast cancer, hormone receptor-positive, Locally advanced or metastatic breast cancer, hormone receptor-positive.
At a glance
| Generic name | faslodex dummy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Selective estrogen receptor degrader (SERD) |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By degrading estrogen receptors, Faslodex prevents estrogen from binding and promoting the growth of breast cancer cells. This mechanism is particularly effective in treating hormone receptor-positive breast cancer.
Approved indications
- Metastatic breast cancer, hormone receptor-positive
- Locally advanced or metastatic breast cancer, hormone receptor-positive
Common side effects
- Hot flashes
- Musculoskeletal pain
- Fatigue
Key clinical trials
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (PHASE3)
- Faslodex Advanced Breast Cancer Local Chinese Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- faslodex dummy CI brief — competitive landscape report
- faslodex dummy updates RSS · CI watch RSS
- AstraZeneca portfolio CI